Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lily Elizabeth Feldman
Observed names:
Lily E. Feldman,
Lily Elizabeth R. Feldman
Institutions:
University of Colorado Anschutz,
University of Colorado Denver
Observed institutions:
University of New Mexico Health Sciences Center,
University of Colorado Anschutz,
University of Colorado Denver
ORCID:
0000-0001-5561-7786
Observed ORCID:
0000-0001-5561-7786
OpenAlex ID:
A5043980936
Adipocyte-derived PGE2 is required for intermittent fasting–induced Treg proliferation and improvement of insulin sensitivity
2022
·
Chunqing Wang
, Xing Zhang
, et al.
·
JCI Insight
·
33
PDF
Depletion of JunB increases adipocyte thermogenic capacity and ameliorates diet-induced insulin resistance
2024
·
Xing Zhang
, Xiaofeng Ding
, et al.
·
Nature Metabolism
·
24
PDF
Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy
2024
·
Lily Elizabeth R. Feldman
, Saswat Mohapatra
, et al.
·
Science Advances
·
11
NPEPPS Is a Druggable Driver of Platinum Resistance
2024
·
Robert T. Jones
, Mathijs Scholtes
, et al.
·
Cancer Research
·
11
PDF
Microbiome-based risk prediction in incident heart failure: a community challenge
2023
·
Pande Putu Erawijantari
, Ece Kartal
, et al.
·
medRxiv
·
6
PDF
Table S2 from Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma
2026
·
Railey G. Mikeska
, Lily Elizabeth R. Feldman
, et al.
Data from Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma
2026
·
Railey G. Mikeska
, Lily Elizabeth R. Feldman
, et al.
Table S3 from Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma
2026
·
Railey G. Mikeska
, Lily Elizabeth R. Feldman
, et al.
Table 1 from Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma
2026
·
Railey G. Mikeska
, Lily Elizabeth R. Feldman
, et al.
Figure S1 from Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma
2026
·
Railey G. Mikeska
, Lily Elizabeth R. Feldman
, et al.
Table S4 from Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma
2026
·
Railey G. Mikeska
, Lily Elizabeth R. Feldman
, et al.
Figue S2 from Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma
2026
·
Railey G. Mikeska
, Lily Elizabeth R. Feldman
, et al.
Table S1 from Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma
2026
·
Railey G. Mikeska
, Lily Elizabeth R. Feldman
, et al.
Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma
2026
·
Railey G. Mikeska
, Lily Elizabeth R. Feldman
, et al.
·
Cancer Research Communications
Abstract A032: Alisertib, a newly defined CBX2 inhibitor, overcomes cisplatin resistance and tumor progression in high grade serous carcinoma (HGSC)
2025
·
Ritsuko Iwanaga
, Tomomi Yamamoto
, et al.
·
Cancer Research
Supplementary Tables from NPEPPS Is a Druggable Driver of Platinum Resistance
2024
·
Robert T. Jones
, Mathijs Scholtes
, et al.
Supplementary Tables from NPEPPS Is a Druggable Driver of Platinum Resistance
2024
·
Robert T. Jones
, Mathijs Scholtes
, et al.
Supplementary Figures from NPEPPS Is a Druggable Driver of Platinum Resistance
2024
·
Robert T. Jones
, Mathijs Scholtes
, et al.
Data from NPEPPS Is a Druggable Driver of Platinum Resistance
2024
·
Robert T. Jones
, Mathijs Scholtes
, et al.
Supplementary Table from NPEPPS Is a Druggable Driver of Platinum Resistance
2024
·
Robert T. Jones
, Mathijs Scholtes
, et al.
Supplementary Tables from NPEPPS Is a Druggable Driver of Platinum Resistance
2024
·
Robert T. Jones
, Mathijs Scholtes
, et al.
Supplementary Tables from NPEPPS Is a Druggable Driver of Platinum Resistance
2024
·
Robert T. Jones
, Mathijs Scholtes
, et al.
Data from NPEPPS Is a Druggable Driver of Platinum Resistance
2024
·
Robert T. Jones
, Mathijs Scholtes
, et al.
Abstract LB256: New mechanistic insights into cisplatin resistance in muscle-invasive bladder cancer
2024
·
Lily Elizabeth R. Feldman
, Saswat Mohapatra
, et al.
·
Cancer Research
Show more works
View as search
Works count:
24
Citation count:
85
H-index:
5
I10-index:
4
Year
Topic
Type